[go: up one dir, main page]

AU706262B2 - Compositions and methods for treating bone deficit conditions - Google Patents

Compositions and methods for treating bone deficit conditions Download PDF

Info

Publication number
AU706262B2
AU706262B2 AU74710/96A AU7471096A AU706262B2 AU 706262 B2 AU706262 B2 AU 706262B2 AU 74710/96 A AU74710/96 A AU 74710/96A AU 7471096 A AU7471096 A AU 7471096A AU 706262 B2 AU706262 B2 AU 706262B2
Authority
AU
Australia
Prior art keywords
bone
substituted
compound
alkyl
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU74710/96A
Other languages
English (en)
Other versions
AU7471096A (en
Inventor
Nand Baindur
Scott M. Harris
Laurence H. Hurley
Sean M. Kerwin
Maria Kontoyianni
Gregory R Mundy
Mark W. Orme
Charles Petrie
Kirk G. Robbins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
OsteoScreen Inc
University of Texas at Austin
Original Assignee
Zymogenetics Inc
OsteoScreen Inc
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc, OsteoScreen Inc, University of Texas at Austin filed Critical Zymogenetics Inc
Publication of AU7471096A publication Critical patent/AU7471096A/en
Application granted granted Critical
Publication of AU706262B2 publication Critical patent/AU706262B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
AU74710/96A 1995-10-23 1996-10-23 Compositions and methods for treating bone deficit conditions Ceased AU706262B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US583095P 1995-10-23 1995-10-23
US60/005830 1995-10-23
PCT/US1996/017019 WO1997015308A1 (fr) 1995-10-23 1996-10-23 Compositions et procedes pour le traitement des deficits osseux

Publications (2)

Publication Number Publication Date
AU7471096A AU7471096A (en) 1997-05-15
AU706262B2 true AU706262B2 (en) 1999-06-10

Family

ID=21717974

Family Applications (1)

Application Number Title Priority Date Filing Date
AU74710/96A Ceased AU706262B2 (en) 1995-10-23 1996-10-23 Compositions and methods for treating bone deficit conditions

Country Status (13)

Country Link
EP (1) EP0866710A4 (fr)
JP (1) JP2000513324A (fr)
KR (1) KR19990067010A (fr)
CN (1) CN1201393A (fr)
AU (1) AU706262B2 (fr)
BR (1) BR9611210A (fr)
CA (1) CA2235481A1 (fr)
CZ (1) CZ115398A3 (fr)
EA (1) EA199800393A1 (fr)
HU (1) HUP9802319A3 (fr)
NO (1) NO981810L (fr)
PL (1) PL327617A1 (fr)
WO (1) WO1997015308A1 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1226245A (zh) * 1996-06-20 1999-08-18 德克萨斯州大学系统董事会 具有药理活性的化合物,其制备方法及其用途
WO1998017267A1 (fr) * 1996-10-23 1998-04-30 Zymogenetics, Inc. Compositions et methodes pour traiter les etats associes a un deficit osseux
US6376476B1 (en) 1996-12-13 2002-04-23 Zymogenetics Corporation Isoprenoid pathway inhibitors for stimulating bone growth
US6080779A (en) * 1996-12-13 2000-06-27 Osteoscreen, Inc. Compositions and methods for stimulating bone growth
AU8748798A (en) * 1997-08-22 1999-03-16 Kyowa Hakko Kogyo Co. Ltd. 4-aminoquinazoline derivatives
US6649631B1 (en) 1997-10-23 2003-11-18 The Board Of Regents Of The University Of Texas System Compositions and methods for treating bone deficit conditions
DE19812204A1 (de) * 1998-03-19 1999-11-04 Plantamed Arzneimittel Gmbh Verwendung von Extrakten aus Cimicifuga racemosa und Belamcanda sinensis als estrogenartiges organselektives Arzneimittel ohne uterotrope Wirkung
JP2000004882A (ja) * 1998-06-18 2000-01-11 Hoechst Marion Roussel Kk ヒトｍｐ５２遺伝子プロモーターおよびこれを用いた有用物質の探索法
US6902721B1 (en) 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6838436B1 (en) 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US6462036B1 (en) 1998-11-06 2002-10-08 Basf Aktiengesellschaft Tricyclic pyrazole derivatives
CA2350235A1 (fr) * 1998-11-06 2000-05-18 Basf Aktiengesellschaft Derives de pyrazole tricyclique
WO2000078351A1 (fr) * 1999-06-18 2000-12-28 Mitsubishi Pharma Corporation Promoteurs de l'osteogenese
AU6865100A (en) * 1999-09-02 2001-04-10 Mitsubishi Pharma Corporation Osteogenesis promoting agents
KR100641802B1 (ko) 1999-12-28 2006-11-02 에자이 가부시키가이샤 술폰아미드 함유 복소환 화합물
FR2806408B1 (fr) * 2000-03-17 2002-10-11 Oreal Composition cosmetique comprenant un derive de furane- naphtoquinone, leur utilisation comme agent colorant et derives
EP1361224B1 (fr) 2000-06-05 2005-12-28 Austria Wirtschaftsservice Gesellschaft mit beschränkter Haftung Hydrazones heterocycliques comme agents anti-cancereux
US6660737B2 (en) 2001-05-04 2003-12-09 The Procter & Gamble Company Medicinal uses of hydrazones
US7119120B2 (en) 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
WO2003082808A1 (fr) * 2002-04-03 2003-10-09 Sumitomo Pharmaceuticals Company, Limited. Derives de benzamide
EP1547996A4 (fr) * 2002-08-30 2006-08-02 Bf Res Inst Inc Sondes de diagnostic et remedes contre des maladies presentant une accumulation de la proteine du prion et methode de marquage
JPWO2004054978A1 (ja) * 2002-12-16 2006-04-20 株式会社 ビーエフ研究所 タウ蛋白蓄積性疾患の診断プローブとしてのキノリン誘導体
TW200505450A (en) 2003-02-03 2005-02-16 Janssen Pharmaceutica Nv Quinoline-derived amide modulators of vanilloid VR1 receptor
JP4848286B2 (ja) 2004-04-30 2011-12-28 武田薬品工業株式会社 複素環アミド化合物及びｍｍｐ−１３阻害剤としてのその用途
PA8663501A1 (es) 2005-02-17 2006-11-09 Wyeth Wyeth Derivados de indol, benzotiofeno, benzofurano e indeno cicloalquilcondensados
CA2676984C (fr) 2007-02-01 2015-03-17 Resverlogix Corp. Composes destines a la prevention et au traitement de maladies cardiovasculaires
WO2009076792A1 (fr) 2007-12-19 2009-06-25 Givaudan Sa Composés rafraîchissants
WO2009158404A1 (fr) 2008-06-26 2009-12-30 Resverlogix Corp. Procédés de préparation de dérivés de quinazolinone
CA2747417C (fr) 2009-01-08 2017-01-03 Resverlogix Corp. Composes pour la prevention et le traitement de maladies cardiovasculaires
US8822462B2 (en) * 2009-01-28 2014-09-02 Emory University Subunit selective NMDA receptor potentiators for the treatment of neurological conditions
JP5795304B2 (ja) 2009-03-18 2015-10-14 レスバーロジックス コーポレイション 新規抗炎症剤
EP3431086B1 (fr) 2009-04-22 2020-06-17 Resverlogix Corp. Nouveaux agents anti-inflammatoires
RS58911B1 (sr) 2011-11-01 2019-08-30 Resverlogix Corp Oralne formulacije sa trenutnim otpuštanjem za supstituisane hinazolinone
EP3147280B1 (fr) 2012-07-18 2018-03-07 University College Dublin, National University of Ireland, Dublin Composé anti-angiogène
CN102942515A (zh) * 2012-10-22 2013-02-27 暨南大学 一种乙烯桥连吲哚化合物及其合成方法和用途
WO2014080290A2 (fr) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Amines cycliques servant d'inhibiteurs de bromodomaines
WO2014080291A2 (fr) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Dérivés biaryle servant d'inhibiteurs de bromodomaines
US9271978B2 (en) 2012-12-21 2016-03-01 Zenith Epigenetics Corp. Heterocyclic compounds as bromodomain inhibitors
CA2977308A1 (fr) 2015-03-13 2016-09-22 Resverlogix Corp. Compositions et procedes therapeutiques pour le traitement de maladies associees au complement
CN107019687B (zh) * 2017-05-08 2020-10-27 上海市伤骨科研究所 N-(4-氯苯基)-3-羟基-2-萘甲酰胺类化合物的用途
CN111116552B (zh) * 2020-01-17 2022-10-11 河北科技大学 一种喹唑啉酮类化合物及其制备方法
CN114469863B (zh) * 2021-11-26 2023-09-26 南方医科大学南方医院 甾醇脂质体作为牙髓和牙本质药物传递系统的应用
CN116650481B (zh) * 2021-12-10 2024-06-14 中南大学湘雅医院 芳香族化合物作为神经丛素蛋白-b2的激活剂以及在制备治疗骨质疏松症药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889851A (en) * 1986-11-21 1989-12-26 Fujisawa Pharmaceutical Co, Ltd. Benzothiadiazine compounds, and pharmaceutical composition comprising the same
JP2724396B2 (ja) * 1987-12-18 1998-03-09 武田薬品工業株式会社 骨粗鬆症予防治療剤
EP0536119A4 (en) * 1989-02-10 1993-08-04 Washington Research Foundation Immunoregulatory agents
JPH06192272A (ja) * 1992-12-24 1994-07-12 Japan Tobacco Inc 新規なトリアゾロベンゾチアジアジン及びトリアゾロベンゾチアジアゼピン誘導体
US5280040A (en) * 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
EP0716086A1 (fr) * 1994-12-09 1996-06-12 Boehringer Mannheim Gmbh Inhibiteurs de métalloprotéinases matricielles à base d'acide malonique
WO1998017267A1 (fr) * 1996-10-23 1998-04-30 Zymogenetics, Inc. Compositions et methodes pour traiter les etats associes a un deficit osseux
JP4269015B2 (ja) * 1996-12-13 2009-05-27 オステオスクリーン アイピー， エルエルシー 骨の成長を刺激する組成物および方法

Also Published As

Publication number Publication date
EP0866710A1 (fr) 1998-09-30
WO1997015308A1 (fr) 1997-05-01
CA2235481A1 (fr) 1997-05-01
EA199800393A1 (ru) 1998-12-24
JP2000513324A (ja) 2000-10-10
KR19990067010A (ko) 1999-08-16
PL327617A1 (en) 1998-12-21
HUP9802319A2 (hu) 1999-02-01
EP0866710A4 (fr) 2001-07-11
CZ115398A3 (cs) 1998-12-16
NO981810D0 (no) 1998-04-22
HUP9802319A3 (en) 1999-12-28
NO981810L (no) 1998-06-22
AU7471096A (en) 1997-05-15
CN1201393A (zh) 1998-12-09
BR9611210A (pt) 1999-12-28

Similar Documents

Publication Publication Date Title
AU706262B2 (en) Compositions and methods for treating bone deficit conditions
US5919808A (en) Compositions and methods for treating bone deficit conditions
US5922753A (en) Methods for treating bone deficit conditions with benzothiazole
US6153631A (en) Compositions and methods for treating bone deficit conditions
US5990169A (en) Compositions and methods for treating bone deficit conditions
US5948776A (en) Compositions and methods for treating bone deficit conditions
US5965573A (en) Compositions and methods for treating bone deficit conditions
US5994358A (en) Compositions and methods for treating bone deficit conditions
US6342514B1 (en) Compositions and methods for treating bone deficit conditions
US6413998B1 (en) Compositions and methods for treating bone deficit conditions
US6251901B1 (en) Compositions and methods for treating bone deficit conditions
WO1997015308A9 (fr) Compositions et procedes pour le traitement des deficits osseux
US6080779A (en) Compositions and methods for stimulating bone growth
EP0944312B9 (fr) Compositions visant a stimuler la croissance osseuse et methodes afferentes
US6649631B1 (en) Compositions and methods for treating bone deficit conditions
US6642216B2 (en) Isoprenoid pathway inhibitors for stimulating bone growth
WO1998025460A9 (fr) Compositions visant a stimuler la croissance osseuse et methodes afferentes
WO1998017267A9 (fr) Compositions et methodes pour traiter les etats associes a un deficit osseux
EP0973513A1 (fr) Compositions et methodes pour traiter les etats associes a un deficit osseux
US5939444A (en) Compositions and methods for treating bone deficit conditions
US6017940A (en) Compositions and methods for treating bone deficit conditions
EP1609469A2 (fr) Compositions et méthodes pour stimuler la croissance osseuse
MXPA98003131A (en) Compositions and methods for the treatment of deficitary conditions of hue
HK1085676A (en) Compositions and methods for stimulating bone growth